This trial looks at whether the medication dupilumab is effective and safe in treating keloids.
1 Primary · 6 Secondary · Reporting Duration: Assessed at Screening, weeks 0, 4, 8, 12, 16, 20, 24
Experimental Treatment
20 Total Participants · 1 Treatment Group
Primary Treatment: Dupilumab · No Placebo Group · Phase 2
Age 18 - 65 · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Connecticut | 50.0% |
Florida | 50.0% |
65+ | 50.0% |
18 - 65 | 50.0% |
Beth Israel Deaconess Medical Center | 100.0% |
Did not meet criteria | 50.0% |
Met criteria | 50.0% |